Manufacturer Quantity Restrictions and Generic vs Brand Name Lenalidomide Use Among Insured Patients
This cohort study assesses patients’ use of brand-name and generic lenalidomide following the first generic market entrant in March 2022.
Authors
- Haiden A. Huskamp (ORCID: https://orcid.org/0000-0002-1860-3956)
- Youngmin Kwon (ORCID: https://orcid.org/0000-0001-8037-5758)
- Stacie B. Dusetzina (ORCID: https://orcid.org/0000-0002-3907-9196)
- Nancy Lynn Keating (ORCID: https://orcid.org/0000-0002-8274-4681)
- Shelley A. Jazowski (ORCID: https://orcid.org/0000-0003-3467-2502)
- Grace Castle
- Yutong (Linda) Lin
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Vanderbilt University (US)
- Vanderbilt-Ingram Cancer Center (US)
- Wake Forest University Health Sciences (US)
- Wake Forest University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.44411
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00